Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

Volume: 11, Pages: 175628561775336 - 175628561775336
Published: Jan 1, 2018
Abstract
BackgroundThe CLARITY and CLARITY Extension studies demonstrated that treatment of relapsing–remitting multiple sclerosis (RRMS) with cladribine tablets (CT) results in significant clinical improvements, compared with placebo. This paper presents the key magnetic resonance imaging (MRI) findings from the CLARITY Extension study. MethodsPatients who received a cumulative dose of either CT 3.5 or 5.25 mg/kg in CLARITY were rerandomized to either...
Paper Details
Title
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
Published Date
Jan 1, 2018
Volume
11
Pages
175628561775336 - 175628561775336
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.